Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

FunMed Pharmacology > Drug Discovery > Flashcards

Drug Discovery Flashcards

1
Q

How do you make a drug candidate

A
  • High throughput screening

- Structure activity relationships

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which properties does the drug need to have

A
  • Type of activity
  • Selectivity of action
  • Bioavailability
  • Safety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is a receptor

A
  • A cellular macromolecule or assembly of macromolecules that are concerned directly and specifically in chemical signalling between and within cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what do most drugs interact with

A

G protein coupled receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe the overview of drug discovery process

A
  • Failure usually happens at the front end
  • Spend £100s of millions, 1/13 compounds entering preclinical development makes it
  • Takes about 15 years – most likely end up in failure
    1. Target selection
    2. Target validation
    3. Lead discovery
    4. Lead optimisation
    5. Preclinical development
    6. Clinical development
    7. Regulatory approval
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does high throughput screening works

A
  • How to find a new molecule
  • Automated robots small sets based on knowledge of target and design, takes about 6 month
  • After 3 more moths, there are confirm HTS and pharmacology, creates a new compound
  • Takes 9 months in total
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do you develop new drugs

A
  • Straight from known compounds
  • DNA encoded library screening
  • Fragment based lead generation
  • Focused screen
  • Structure based design
  • Random high throughput screen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

describe the process of screening

A
  • Potency – is it potent enough
  • Selectivity – what else does the molecule affect, side effects
  • Pharmacokinetics – how long does it staying the body, how does it get into the brain, will it get past acid/peptidases in stomach, metabolites
  • Pharmacodynamics – efficacy in vivo
  • Efficacy in animal disease model
  • Safe when given acutely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe selectivity of action

A
  • defines the ability of a drug to act against a range of receptors, channels and enzymes – activity may be associated with unwanted side effects
  • drugs can be poisonous
  • risk: benefit analysis – non life threatening disorders often demand a high therapeutic index (want drug to be really safe), life threatening disorders may be able to tolerate side effects (can trade of side effects for helping you survive)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe the desired pharmacokinetic properties

A
  • this is how the body affects a specific chemical after administration
  • routes of drug administration – they all have pharmokinetic advatnages and disadvantages
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe what the drug needs to survive

A

If orally-administered
• Needs to survive the acid/ peptidase in the stomach

Drugs are metabolised
• Especially by the liver
• Cytochrome P450 enzymes – oxidse and degrade drugs – design molecule to overcome this
• Metabolites can have biological activity

Drugs or their metabolites are excreted
• Urine
• Faeces

Restricted drug distribution
• Blood-Brain Barrier
• Restriction to the gut lumen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what does the toxicology and safety assessment do

A

this is to determine safe doses of exposure in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does the toxicology and safety assessment include

A 
In vitro includes 
-	Mutagenicity in bacteria (Ames test)
-	Mammalian microsomal enzyme test 
In vivo includes
-	Acute oral 
-	Sub chronic (14-180 days)
-	Toxicity to reproductive systems (2 generations; birth defects)
-	Chronic studies, including 90 day sub-chronic study and 2 year chronic study (carcinogensis)
-	Effects of metabolites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is phase I about

A

tolerance and safety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is phase II about

A

proof of concept and getting the dose right

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is phase III about

A

cost of money

17
Q

Describe Phase I

A
  • Small numbers
  • Imeediate response to a new drug
  • Small doseases
  • Escalated dose until effect seen
  • Tolerability assessed
  • Pharmackokientics studied
  • Short term studies
  • Single dose per volunteer usually
18
Q

describe the accident that happened with phase I

A
  • 90 people tested, one dead, 5 hospitlaised

- Biotrial – French contract research organisation

19
Q

describe phase II

A
  • Patient groups
  • Small numbers studied intensively
  • Pharmacological assessment – kinetics
  • Efficacy – does it work in the clinical setting
  • Tolerability in target group – unwanted effects
20
Q

describe Phase III

A
  • More patients
  • Studied less intensively
  • Usually controlled designs
  • Compare versus established therapy or placebo
  • Identify optimum dose
  • Checks methods of administration
  • Establish indications for the drug
  • Prepare for licensing of the drug
  • Must establish a case for the new drug
  • Negotiations with regulators
  • Additional studies if required
21
Q

what is the problem with phase III

A
  • 90% of total drug development is greater than 1 billion pounds
22
Q

how is the authorisation process determined

A
  • Application from pharmaceutical company
  • Detailed supporting dossier
  • Assessment by toxicologist, pharmacist and physician
  • Assessment report reviewed by expert advisory committee
  • Decision to grant or refuse made by competent authority
23
Q

what do they make decisions based on

A
  • Safety
  • Quality
  • Efficacy
  • Cost is not taken in to account
24
Q

how does patent protection work

A
  • Novel intellectual property protected from patenting
  • After a patent is filed it is not published for 18 months
  • After a patent is granted the holder has exclusive rights for 20 years
  • The invention is usually long before commercialisation so time to recover costs and make profits takes 5-12 years
25
Q

what is phase 4

A

this is post marketing surveillance

26
Q

describe phase 4

A
  • After initial licensing
  • Extend indications for drugs
  • Refine target group
  • Interaction studies – perhaps responding to case reports
  • Why do some fail to respond
  • Continuous process
27
Q

what are the bad things that are associated with medicine

A
  • 5% of all hospital admissions are due to ADRS
  • 5% of all hospital patietns suffer an ADR
  • 5th most common cause of death
  • 197,000 deaths in EU from ADR
  • Cost of ADRs cost 79 billion euro a year
  • This can be reduced by pharmacovigilance
28
Q

justifying R and D

A

R&D costs are huge
- Only 3 in 10 are profitable with one of those becoming a blockbuster with $1bn revenue a year
- Many more do not make it to market ]
Wider view needs to be used
- Use drugs, don’t need surgery, can continue to support family

29
Q

what are the 3 examples of how drugs can go wrong

A
  • sustainability
  • choosing the right and wrong indication
  • trial design can trip you up
30
Q

describe sustainability

A

Sustainability
- Antibiotic resistance is spreading
- Pharmaceuticals companies no longer producing antibiotics
How do we get around this
- Propose a new commercial model
- This means that return on investment is not based on number of prescriptions sold but on lump sum from government or group of governments therefore no need to market or encourage people to use it

31
Q

describe choosing the right and wrong indication and how that is critical

A
  • 5-HT3 – stopped nausea and vomiting of chemotherapy, but it caused mild constipation
  • People started dying causes was not clear
  • Introduced later but under severe restrictions
  • Positive revolutionized cancer treatment, but people died and funding lost
32
Q

describe how trial design can trip you up

A

Trail design can trip you up – neuropathic pain
- Usually poorly treated
- 84 randomised control trials using 92 drugs versus a placebo
- Baseline ratings did not change over 23 years
- Placebo response over time increased and pain baseline decreased so placebo works better than the drugs
- Longer trials, larger trials, greater contrast research organisation caused increase in placebo responses
Cost of drugs
Some drugs cost up to $100,000 for a full course, but cost of manufacturing is a tiny fraction of this

FunMed Pharmacology (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions